Kathleen R. Lamborn

Medicine · Health Sciences

93h-index31.5kcitations361works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(190), Brain Metastases and Treatment(53), Radiopharmaceutical Chemistry and Applications(39), Meningioma and schwannoma management(32), Cancer, Hypoxia, and Metabolism(30)

Publications361 total

Supplementary Tables 1-8 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Figure and Table Legends, Methods from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Figure and Table Legends, Methods from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Interview with Dr. Mellinghoff from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Data from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Figures 1-10 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Tables 1-8 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Data from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Interview with Dr. Mellinghoff from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Figures 1-10 from Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
2023Open Access
Supplementary Table Legend from Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2023Open Access
Data from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
2023Open Access
Supplementary Table Legend from Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2023Open Access
Data from Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2023Open Access
Supplementary Table 2 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
2023Open Access
Supplementary Table 1 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
2023Open Access
Supplementary Table 1 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
2023Open Access
Data from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
2023Open Access
Supplementary Table 1 from Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2023Open Access
Supplementary Table 1 from Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Michael D. Prados(24), Susan M. Chang(15), Mitchel S. Berger(13), Patrick Y. Wen(10), Timothy F. Cloughesy(10), Minesh P. Mehta(9), Penny K. Sneed(9), David A. Larson(9), Mark R. Gilbert(8), Susan M. Chang(8), Lisa M. DeAngelis(8), Michael W. McDermott(7), Frank S. Lieberman(7), H. Ian Robins(7), John G. Kuhn(7), William M. Wara(7), Andrew B. Lassman(6), Edward F. Chang(6), Mary Malec(6), Philip H. Gutin(6)